These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27167227)

  • 21. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N; Michelis MF; Matalon A
    BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
    Bertonsello-Catto VR; Lucca LJ; da Costa JAC
    Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.
    Jalal D; McFadden M; Dwyer JP; Umanath K; Aguilar E; Yagil Y; Greco B; Sika M; Lewis JB; Greene T; Goral S
    Hemodial Int; 2017 Apr; 21(2):243-249. PubMed ID: 27615161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction to: Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end-stage renal disease.
    Umeukeje EM; Merighi JR; Browne T; Wild M; Alsmaan H; Umanath K; Lewis JB; Wallston KA; Cavanaugh KL
    J Behav Med; 2019 Apr; 42(2):376-379. PubMed ID: 30623275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.
    Wang S; Alfieri T; Ramakrishnan K; Braunhofer P; Newsome BA
    Nephrol Dial Transplant; 2014 Nov; 29(11):2092-9. PubMed ID: 24009281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
    Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
    BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bone and mineral disorder of children undergoing chronic peritoneal dialysis.
    Borzych D; Rees L; Ha IS; Chua A; Valles PG; Lipka M; Zambrano P; Ahlenstiel T; Bakkaloglu SA; Spizzirri AP; Lopez L; Ozaltin F; Printza N; Hari P; Klaus G; Bak M; Vogel A; Ariceta G; Yap HK; Warady BA; Schaefer F;
    Kidney Int; 2010 Dec; 78(12):1295-304. PubMed ID: 20811335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing serum phosphate in haemodialysis patients: time for an innovative approach?
    Collinson A; McMullan M; Tse WY; Sadler H
    Eur J Clin Nutr; 2014 Mar; 68(3):392-6. PubMed ID: 24424075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment adherence and perception in patients on maintenance hemodialysis: a cross - sectional study from Palestine.
    Naalweh KS; Barakat MA; Sweileh MW; Al-Jabi SW; Sweileh WM; Zyoud SH
    BMC Nephrol; 2017 May; 18(1):178. PubMed ID: 28558719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.
    Johansen KL; Chertow GM
    J Ren Nutr; 2007 Sep; 17(5):305-13. PubMed ID: 17720099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.